NEWS
PROFILUX Lung Cancer diagnostic project receives funding from the EU Eurostars Programme and CDTI
April 1st, 2020 The project proposal named ‘PROFILUX – Saliva- and blood-based lung cancer detection based on tumour auto-antibody profiling’ has been selected to receive funding from the EU Eurostars Programme. The company received the official communication in January and the project started on April. The international research consortium where PROALT participates is leaded by [...]
Successful start of the clinical validation study of COLODETECT® test
23rd, April 2019 Protein Alternatives S.L. (PROALT) has begun the clinical validation study of its blood-based diagnostic test for colorectal cancer in Luminex® and ELISA-based formats. COLODETECT® test is based on detecting in blood the autoantibodies (AAbs) generated by the human body against proteins related to the colorectal cancer tumor, known as tumor-associated antigens [...]
PROALT attended the 9th International Biotechnology Meeting, BIOSPAIN 2018
1st, October 2018 From September 25 to 27, the meeting organized by ASEBIO and the Junta de Andalucía brought together in Seville the largest national and international agents in the biotechnology sector. PROALT has participated in the partnering event and met during these days with investors, customers and potential commercial and technological partners. The company [...]
PROALT attended the BIO International Convention 2018. Boston, MA (USA)
Photo: partnering meetings at BIO 2018. 6th, June 2018 PROALT has participated in the partnering event at BIO International Convention in Boston, MA (USA), to present the latest advances of COLODETECT, the non-invasive test in development by the company that will allow early detection of colorectal cancer (CCR) in patients affected by this disease, even [...]
PROALT attended the 12th BioEurope Spring conference and partnering event
14th, March 2018 BIOEUROPE SPRING 2018 is the premier springtime partnering conference for the biotechnology industry. Amsterdam, The Netherlands. 12th-14th March 2018. The company participated in the conference and partnering event to promote its activities in colorectal cancer diagnostic and therapeutic fields, highlighting the latest progresses. Investors had the chance to update about the of [...]
